Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Bitcoin momentum builds in Abu Dhabi as global interest surges - 2One of the best meteor showers of the year peaks at the worst possible time this week
- 3Indoor Drinking Fountains: Famous Home Advancements during the Pandemic
- 4Italy's Beloved Trevi Fountain Hides A Unique Secret That Can Be Explored Underground
- 5NASA's Perseverance Mars rover could break the record for miles driven on another planet
- NASA releases new photos of interstellar comet 3I/ATLAS
- Iran warns its ready to open new front in Yemen, close Bab al-Mandab Strait with Houthis
- Sound Propensities: 20 Methods for helping Your Insusceptible Framework
- From Overpowered to Coordinated: Individual Accounts of Cleaning up
- Accor signs agreement to transform El Gouna resort as Sofitel
- 4 Creative Savvy Home Gadgets of 2024: Reforming Home Robotization and Security
- 5 State of the art Advancements in Computer generated Simulation
- From Loner to Force to be reckoned with: Individual Accounts of Change
- Former 'Bachelorette' welcomes 1st baby via emergency c-section
